Reduced anti-parkinsonian effect of levodopa, worsening of tremor and rigidity.
Avoid concomitant use. If unavoidable, monitor for reduced efficacy of levodopa and consider dose adjustment of levodopa.
PDE-4 inhibitor, Non-anticholinergic smooth muscle antispasmodic · Antispasmodic
Drotaverine is a novel non-anticholinergic smooth muscle antispasmodic which acts by inhibiting phosphodiesterase-4 (PDE-4) selectively for smooth muscle. This leads to elevation of intracellular cAMP/cGMP, attending smooth muscle relaxation. Changes in membrane ionic fluxes and membrane potential have also been shown.
Reduced anti-parkinsonian effect of levodopa, worsening of tremor and rigidity.
Avoid concomitant use. If unavoidable, monitor for reduced efficacy of levodopa and consider dose adjustment of levodopa.
Increased risk of orthostatic hypotension, dizziness, and syncope.
Monitor blood pressure, especially during initiation or dose changes. Advise patients to stand up slowly.
Increased sedation, dizziness, and impaired psychomotor function.
Advise caution when driving or operating machinery. Monitor for excessive sedation.
Increased sedation, dizziness, and impaired psychomotor function.
Advise caution when driving or operating machinery. Monitor for excessive sedation.
Increased risk of anticholinergic side effects such as dry mouth, constipation, urinary retention, and blurred vision.
Monitor for increased anticholinergic side effects. Consider alternative antispasmodics if these effects are bothersome.
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e·Verified: 2026-05-10 · House clinical team